- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01526135
Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma
Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma
Study Overview
Status
Intervention / Treatment
Detailed Description
STUDY DESIGN/ Evaluation criteria Main criterion: efficacy The main criterion is the disease-free survival at 3 years. Disease-free survival is the time delay between the date of randomization and the date at which the 1st cancer-related event such as local relapse, distant metastasis, a second cancer or death from any cause is observed. Patients without event at the time of anlaysis will be censored at the date of last follow-up visit.
Locoregional relapse is a disease relapse occurring at the site of primary resection, in the pancreas or in the associated regional lymph nodes.
Metastatic relapse is the distant disease recurrence involving any possible sites of relapse (peritoneal, hepatic, pulmonary, and distant lymph nodes).
Secondary criteria Overall and specific survival Overall survival is the time delay between the date of randomization and the patient's death, irrespective of its cause. Patients who are still living at the time of analysis will be censored at the date of last follow-up visit.
Specific survival is the time delay between the date of randomization and the patient's death due to the treated cancer or a treatment-related complication.
Metastasis-free survival Metastasis-free survival is the time delay between the date of randomization and the date of the 1st distant event occurrence (peritoneal, hepatic, pulmonary, and lymph nodes). Loco-regional events will be discarded and patients still living without metastasis at the time of analysis will be censored at the date of last follow-up examination objectively assessing this type of event.
Tolerance Patients evaluable for toxicity must have received at least one course or injection of the treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Moncton, Canada, E1C 6Z8
- The Moncton Hospital
-
Quebec, Canada, G1R 2J6
- CHUQ - Hôtel-Dieu de Québec
-
Sault Ste. Marie, Canada, P6B 0A8
- Algoma District Cancer Program, Sault Area Hospital
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Centre
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BCCA - Vancouver Cancer Centre
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
- CancerCare Manitoba, St. Boniface General Hospital
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1C 8X3
- Dr Leon Richard Oncology Centre
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- The Royal Victoria Hospital - Cancer Care Program
-
Hamilton, Ontario, Canada, L8V 5C2
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Kingston, Ontario, Canada, K7L 5P9
- Cancer Centre of Southeastern Ontario at Kingston General Hospital
-
Ottawa, Ontario, Canada, K1H 8L6
- Ottawa Health Research Institute
-
St. Catharines, Ontario, Canada, L2S 0A9
- Niagara Health System
-
Sudbury, Ontario, Canada, P3E 5J1
- Department of Medical Oncology Health Sciences North
-
Toronto, Ontario, Canada, M5G 2C4
- General Surgery - TGH Site, Univ. Health Network
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 4M1
- CHUM - Hopital Notre-Dame
-
Montreal, Quebec, Canada, H2W 1S6
- McGill University (Department of Oncology)
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allain Blair Cancer Centre
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Saskatoon Cancer Centre, University of Saskatchewan
-
-
-
-
-
Amiens, France
- CHU Nord
-
Angers, France
- ICO Paul Papin
-
Bobigny, France
- Hôpital Avicenne
-
Bordeaux, France
- Institut Bergonie
-
Caen, France
- CHU Côte de Nacre
-
Clichy, France
- Hopital Beaujon
-
Colmar, France
- Hôpital Louis Pasteur
-
Dijon, France
- CHU de Dijon - Site Bocage
-
La Roche Sur Yon, France
- CHD Vendée
-
Lille, France
- Hopital Huriez
-
Lyon, France
- Centre Leon Berard
-
Lyon, France
- Hopital Privé Jean Mermoz
-
Lyon, France
- Hôpital de la Croix-Rousse
-
Marseille, France
- Institut Paoli Calmettes
-
Marseille, France
- CHU Nord
-
Marseille, France
- CHU Timone Adulte
-
Marseille, France
- Fondation Ambroise Paré / Hôpital Européen
-
Mont de Marsan, France
- CH Layne
-
Montpellier, France
- CHU De ST Eloi
-
Montpellier, France
- CRCL Val d'Aurelle
-
Nice, France
- Centre Antoine-Lacassagne
-
Orleans, France
- CHR Orléans - La Source
-
Paris, France
- Groupe hospitalier Paris Saint Joseph
-
Paris, France
- Groupe Hospitalier Pitie-Salpetriere
-
Perpignan, France
- Hôpital Saint-Jean
-
Pessac, France
- Hôpital Haut-Lévêque
-
Reims, France
- Centre hospitalier de Reims
-
Rouen, France
- CHU Rouen
-
Saint Herblain, France
- Centre Rene Gauducheau
-
Strasbourg, France
- Centre PAUL STRAUSS
-
Tours, France
- Hopital Trousseau
-
Vandoeuvre Les Nancy, France
- Centre Alexis Vautrin
-
Vandœuvre-lès-Nancy, France
- Hôpital de Brabois-CHU de Nancy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically proven pancreatic ductal adenocarcinoma. Intraductal papillary mucinous tumor of the pancreas (IPMT) with invasive components are eligible.
- Macroscopically complete resection (R0 or R1 resection).
- Patients aged from 18 to 79 years.
- WHO performance status 0-1.
- No prior radiotherapy and no previous chemotherapy.
- Full recovery from surgery and patient able to receive chemotherapy: adequate oral nutrition of ≥1500 calories per day and free of significant nausea and vomiting.
- Adequate hematologic function (Absolute neutrophil count ANC ≥1,500 cells/mm³, platelets ≥100 000 cells/mm³ and hemoglobin ≥10 g/L - possibly after transfusion -).
- Serum total bilirubin ≤1.5 times the institutional upper limit of normal.
- Creatinine level <130 micromol/L (14.7 mg/L).
- Patient of child-bearing potential (for female patient: study entry after a menstrual period and a negative pregnancy test) must agree to use two medically acceptable methods of contraception (one for the patient and one for the partner) during the study and for 4 months after the last study treatment intake for women and 6 months for men.
- Interval since surgery between 21 and 84 days.
- Patient information and signed informed consent.
- Public or private health insurance coverage.
Exclusion Criteria:
- Other types of non-ductal tumor of the pancreas, including endocrine tumors or acinar cell adenocarcinoma, cystadenocarcinoma and malignant ampulloma.
- Metastases (including ascites or malignant pleural effusion).
- Macroscopic incomplete tumor removal (R2 resection).
- CA 19-9 > 180 U/ml within 21 days of registration on study.
- No heart failure or coronary heart disease symptoms.
- No major comorbidity that may preclude the delivery of treatment or active infection (HIV or chronic hepatitis B or C) or uncontrolled diabetes.
- Pre-existing neuropathy, Gilbert's disease or genotype UGT1A1 * 28 / * 28.
- Inflammatory disease of the colon or rectum, or occlusion or sub-occlusion of the intestine or severe postoperative uncontrolled diarrhea.
- Concomitant occurrence of another cancer, or history of cancer except in situ carcinoma of the cervix treated or basal cell carcinoma or squamous cell carcinoma.
- Fructose intolerance.
- Persons deprived of liberty or under guardianship.
- Psychological, familial, sociological or geographical condition potentially. hampering compliance with the study protocol and follow-up schedule.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A GEMCITABINE
Arm A : Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
|
Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
|
Experimental: Arm B mFOLFIRINOX
Arm B : mFOLFIRINOX every 14 days, 12 cycles, 24 weeks. Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started. Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours. 5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day) |
mFolfirinox every 14 days, 12 cycles, 24 weeks. mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started. Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours. 5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
disease-free survival (DFS)
Time Frame: 3 YEARS
|
to compare disease-free survival (DFS) at 3 years between the experimental and control arms.
|
3 YEARS
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: 36 MONTHS
|
36 MONTHS
|
Specific survival
Time Frame: 36 MONTHS
|
36 MONTHS
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Thierry CONROY, PROF, Centre Alexis Vautrin-VANDOEUVRE LES NANCY
Publications and helpful links
General Publications
- Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouche O, Monard L, Lambert A, Hammel P; Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncol. 2022 Nov 1;8(11):1571-1578. doi: 10.1001/jamaoncol.2022.3829. Erratum In: JAMA Oncol. 2022 Nov 23;:
- Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Chone L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
Other Study ID Numbers
- Prodige 24 / Accord 24
- NCIC CTG PA.6 (Other Identifier: NCIC)
- 2011-002026-52 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
-
Georgetown UniversityERYtech PharmaActive, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Gilead SciencesTerminatedPreviously Untreated Pancreatic Ductal Adenocarcinoma | Relapsed/Refractory Pancreatic Ductal AdenocarcinomaUnited States
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | Primary Pancreatic Ductal AdenocarcinomaUnited States
-
Sohag UniversityCompletedPancreatic Adenocarcinoma
-
UMC UtrechtDutch Pancreatic Cancer Group (DPCG)Enrolling by invitationResectable Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Ductal AdenocarcinomaNetherlands
-
Jonsson Comprehensive Cancer CenterArcus Biosciences, Inc.SuspendedBorderline Resectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbRecruitingPancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)United States
-
University Hospital, RouenFederation Francophone de Cancerologie Digestive; UNICANCER; Federation of Research... and other collaboratorsUnknownResectable Pancreatic Duct AdenocarcinomaFrance
Clinical Trials on Gemcitabine
-
AstraZenecaRecruitingBiliary Tract CancerFrance, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
-
Sierra Oncology LLC - a GSK companyCompletedAdvanced Solid TumorsSpain, United Kingdom
-
University of Erlangen-Nürnberg Medical SchoolActive, not recruiting
-
Shenzhen University General HospitalNot yet recruiting
-
3D Medicines (Sichuan) Co., Ltd.Not yet recruitingBiliary Tract Neoplasms
-
Kansai Hepatobiliary Oncology GroupCompleted
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
3D Medicines (Sichuan) Co., Ltd.RecruitingBiliary Tract NeoplasmsChina
-
Yung NAQueen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern HospitalRecruitingMuscle-Invasive Bladder Carcinoma | Muscle Invasive Bladder Urothelial CarcinomaHong Kong
-
Air Force Military Medical University, ChinaRecruiting